Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Bristow

Showing results (1-10 of 183) with videos related to

Pageof 19
Sort By:
Pharmacology & Therapeutics|January 28, 2012
Pharmacogenetic targeting of drugs for heart failureMichael R Bristow
Journal of the American College of Cardiology|April 8, 2003
Microarray measurements of gene expression before and after left ventricular assist device placementMichael R Bristow
International Journal of Cardiology|December 19, 2017
Contractile reserve and the response to cardiac resynchronization therapyMichael R Bristow
American Journal of Physiology. Heart and Circulatory Physiology|August 1, 2006
Cardiac resynchronization therapy and adrenergic mechanismsMichael R Bristow
European Journal of Heart Failure|March 3, 2017
Genetic variation expressed in the brain may impact heart failureMichael R Bristow
Circulation Research|October 29, 2011
Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiologyMichael R Bristow
JACC. Heart Failure|October 13, 2014
Polymorphic variation in the G-protein beta-3 subunit gene and response to BiDil in A-HeFT: Basis for an African-American pharmacogenetic advantage to nitric oxide donor therapy?Michael R Bristow
Heart Failure Clinics|September 20, 2011
Pharmacogenetics in heart failure trialsMona Fiuzat, Michael R Bristow
JACC. Basic to Translational Science|September 1, 2018
Fine Tuning Adenylyl Cyclase as a (Gene) Therapy for Heart FailureJ David Port, Michael R Bristow
JACC. Basic to Translational Science|March 8, 2022
Cardiac Adrenergic Activation in Heart Failure With Preserved Ejection Fraction: A Role for β-Blockade?Michael R Bristow, Douglas L Mann
Pageof 19

Showing results (1-10 of 183) with videos related to

Sort By:
Pageof 19
Pharmacology & Therapeutics|January 28, 2012
Pharmacogenetic targeting of drugs for heart failureMichael R Bristow
Journal of the American College of Cardiology|April 8, 2003
Microarray measurements of gene expression before and after left ventricular assist device placementMichael R Bristow
International Journal of Cardiology|December 19, 2017
Contractile reserve and the response to cardiac resynchronization therapyMichael R Bristow
American Journal of Physiology. Heart and Circulatory Physiology|August 1, 2006
Cardiac resynchronization therapy and adrenergic mechanismsMichael R Bristow
European Journal of Heart Failure|March 3, 2017
Genetic variation expressed in the brain may impact heart failureMichael R Bristow
Circulation Research|October 29, 2011
Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiologyMichael R Bristow
JACC. Heart Failure|October 13, 2014
Polymorphic variation in the G-protein beta-3 subunit gene and response to BiDil in A-HeFT: Basis for an African-American pharmacogenetic advantage to nitric oxide donor therapy?Michael R Bristow
Heart Failure Clinics|September 20, 2011
Pharmacogenetics in heart failure trialsMona Fiuzat, Michael R Bristow
JACC. Basic to Translational Science|September 1, 2018
Fine Tuning Adenylyl Cyclase as a (Gene) Therapy for Heart FailureJ David Port, Michael R Bristow
JACC. Basic to Translational Science|March 8, 2022
Cardiac Adrenergic Activation in Heart Failure With Preserved Ejection Fraction: A Role for β-Blockade?Michael R Bristow, Douglas L Mann
Pageof 19